CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients

Seven years ago a chronic lymphocytic leukemia patient was for the first time successfully treated with chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) to target CD19 overexpression in tumor cells. This was the beginning of the development of a new type of immunotherapy treatment in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez-Amill, Lorena, Marzal, Berta, Urbano-Ispizua, Alvaro, Juan, Manel, Martín-Antonio, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256819/
https://www.ncbi.nlm.nih.gov/pubmed/30185400
http://dx.doi.org/10.4274/tjh.2018.0196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256819/
https://www.ncbi.nlm.nih.gov/pubmed/30185400
http://dx.doi.org/10.4274/tjh.2018.0196

Ejemplares similares